GSK: Still reasons to be cheerful rather than fearful after 'nightmare' MondayProactive Investors • 06/04/24
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuitsCNBC • 06/03/24
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancerBusiness Wire • 06/03/24
GSK: Zantac litigation obscures the positives, says leading investment bankProactive Investors • 06/03/24
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myelomaBusiness Wire • 06/02/24
GSK says late-stage trials of potential blockbuster asthma drug met their goalsMarket Watch • 05/21/24